iShares US Pharmaceuticals ETF
IHE
IHE
95 hedge funds and large institutions have $133M invested in iShares US Pharmaceuticals ETF in 2018 Q2 according to their latest regulatory filings, with 9 funds opening new positions, 10 increasing their positions, 43 reducing their positions, and 15 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more ownership
Funds ownership: →
less capital invested
Capital invested by funds: $ → $
less funds holding
Funds holding: →
40% less first-time investments, than exits
New positions opened: 9 | Existing positions closed: 15
77% less repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 43
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Holders
95
Holding in Top 10
–
Calls
$4.53M
Puts
$1.18M
Top Buyers
| 1 | +$2.67M | |
| 2 | +$2.52M | |
| 3 | +$2.05M | |
| 4 |
MGIA
Matthew Goff Investment Advisor
Houston,
Texas
|
+$678K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
+$521K |
Top Sellers
| 1 | -$4.29M | |
| 2 | -$3.14M | |
| 3 | -$2.84M | |
| 4 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$1.18M |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$989K |